[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2013036031A3 - Composition pharmaceutique comprenant un inhibiteur de l'expression du miarn486 en tant que principe actif dans la prévention et le traitement de troubles neurologiques - Google Patents

Composition pharmaceutique comprenant un inhibiteur de l'expression du miarn486 en tant que principe actif dans la prévention et le traitement de troubles neurologiques Download PDF

Info

Publication number
WO2013036031A3
WO2013036031A3 PCT/KR2012/007112 KR2012007112W WO2013036031A3 WO 2013036031 A3 WO2013036031 A3 WO 2013036031A3 KR 2012007112 W KR2012007112 W KR 2012007112W WO 2013036031 A3 WO2013036031 A3 WO 2013036031A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
neurological disorders
pharmaceutical composition
treating neurological
active ingredient
Prior art date
Application number
PCT/KR2012/007112
Other languages
English (en)
Korean (ko)
Other versions
WO2013036031A2 (fr
Inventor
강수경
Original Assignee
서울대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서울대학교 산학협력단 filed Critical 서울대학교 산학협력단
Publication of WO2013036031A2 publication Critical patent/WO2013036031A2/fr
Publication of WO2013036031A3 publication Critical patent/WO2013036031A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant un inhibiteur de l'expression de miARN486 en tant que principe actif dans la prévention et le traitement de troubles neurologiques. Plus particulièrement, comme il a été confirmé que l'interférence avec l'expression de miR486 au moyen d'un inhibiteur de miR486 surmontait l'inhibition de NeuroD6, induisant ainsi des améliorations dans les lésions médullaires ou SCI, l'inhibiteur du miR486 peut être utilisé en tant que principe actif dans une composition pharmaceutique destinée à la prévention et au traitement de troubles neurologiques; en outre, le mécanisme selon lequel le miR486 régule l'expression de NeuroD6 peut être appliqué dans le criblage de substances candidates destinées à la prévention et au traitement de troubles neurologiques.
PCT/KR2012/007112 2011-09-06 2012-09-05 Composition pharmaceutique comprenant un inhibiteur de l'expression du miarn486 en tant que principe actif dans la prévention et le traitement de troubles neurologiques WO2013036031A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110090424A KR20130026950A (ko) 2011-09-06 2011-09-06 ｍｉｃｒｏＲＮＡ４８６ 발현 억제제를 유효성분으로 포함하는 신경계 질환 예방 및 치료용 약학적 조성물
KR10-2011-0090424 2011-09-06

Publications (2)

Publication Number Publication Date
WO2013036031A2 WO2013036031A2 (fr) 2013-03-14
WO2013036031A3 true WO2013036031A3 (fr) 2013-07-11

Family

ID=47832704

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/007112 WO2013036031A2 (fr) 2011-09-06 2012-09-05 Composition pharmaceutique comprenant un inhibiteur de l'expression du miarn486 en tant que principe actif dans la prévention et le traitement de troubles neurologiques

Country Status (2)

Country Link
KR (1) KR20130026950A (fr)
WO (1) WO2013036031A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102304041B1 (ko) 2019-12-24 2021-09-24 경북대학교 산학협력단 microRNA 억제제를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100049079A (ko) * 2007-07-18 2010-05-11 더 리젠트스 오브 더 유니버시티 오브 콜로라도 인간의 정상 심장과 기능부진 심장에서 마이크로 ｒｎａ의 차등 발현
WO2010054386A2 (fr) * 2008-11-10 2010-05-14 Battelle Memorial Institute Procédés, compositions et dispositifs utilisant du microarn pour déterminer des conditions physiologiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100049079A (ko) * 2007-07-18 2010-05-11 더 리젠트스 오브 더 유니버시티 오브 콜로라도 인간의 정상 심장과 기능부진 심장에서 마이크로 ｒｎａ의 차등 발현
WO2010054386A2 (fr) * 2008-11-10 2010-05-14 Battelle Memorial Institute Procédés, compositions et dispositifs utilisant du microarn pour déterminer des conditions physiologiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOHAMMAD M. GHAHRAMANI SENO ET AL.: "Gene and miRNA expression profiles in autism spectrum disorders", BRAIN RESEARCH, vol. 1380, 22 March 2011 (2011-03-22), pages 85 - 97, XP028161669 *

Also Published As

Publication number Publication date
WO2013036031A2 (fr) 2013-03-14
KR20130026950A (ko) 2013-03-14

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
WO2015168532A3 (fr) Compositions et procédés de modulation de l'expression de pkk
IN2014DN09805A (fr)
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
WO2010008831A3 (fr) Composés et procédés pour moduler les récepteurs couplés à la protéine g
WO2011103202A3 (fr) Modulateurs du récepteur des androgènes et leurs utilisations
WO2014144100A3 (fr) Stimulateurs de sgc
WO2008094737A3 (fr) Composés et compositions servant en tant qu'inhibiteurs de kinases
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
WO2009036175A3 (fr) Inhibiteur de f1f0-atpase et procédés associés
IN2014DN09804A (fr)
WO2011090270A3 (fr) Composition contenant de l'osmotine pour prévenir et traiter des troubles neurologiques
WO2012106393A3 (fr) Withanolide isolé à partir de physalis longifolia et ses analogues et procédés d'utilisation
IL195217A0 (en) Protein kinase inhibitors and uses thereof
EP3266317A4 (fr) Composition pour prévenir, améliorer ou traiter des troubles neurologiques, contenant un peptide d'osmotine comme principe actif
EP3122872A4 (fr) Compositions et méthodes destinées à traiter le diabète de type 1 et type 2 et autres troubles associés
EP3182979A4 (fr) Nouvelles compositions et méthodes utiles pour traiter ou prévenir des maladies ou des troubles hépatiques et favoriser la perte de poids
WO2013170072A3 (fr) Composés pour le traitement de troubles neurologiques
WO2012158672A3 (fr) Composés utilisés dans le traitement de la mucosite
WO2015015378A3 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
EP3352755A4 (fr) Nouveaux composés, compositions et méthodes pour le traitement de troubles cutanés
WO2012106427A3 (fr) Procédés de traitement d'ulcères du pied diabétique
EP3677265A4 (fr) Composition pour prévenir ou traiter les troubles du sommeil
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
WO2012017321A3 (fr) Traitement de la dyslipidémie

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12829806

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12829806

Country of ref document: EP

Kind code of ref document: A2